Clinical Trials on Vorübergehendes myeloproliferatives Syndrom

Total 35025 results

M.D. Anderson Cancer Center

Not yet recruiting

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Myeloproliferative Neoplasm | Myelodysplastic Neoplasm | Pathway Mutant Myelodysplastic Syndromes

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Cholecalciferol in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes

Myelodysplastic Syndromes | Myelodysplastic/Myeloproliferative Neoplasms

United States, Canada, Australia, Puerto Rico
CTI BioPharma
National Cancer Institute (NCI)

Terminated

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
National Cancer Institute (NCI)

Not yet recruiting

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Myelodysplastic Syndromes

United States
Fallon Clinic

Completed

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Anemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Stanford University
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb

Recruiting

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

Myelodysplastic Syndromes | Anemia | Myeloproliferative Neoplasm

United States
University of Washington

Completed

Interleukin-2 in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

Myelodysplastic Syndromes | Myeloproliferative Neoplasm

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Case Comprehensive Cancer Center

Completed

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder

Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Diseases

United States
BeiGene

Recruiting

A Study of BGB-11417 in Participants With Myeloid Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelodysplastic/Myeloproliferative Neoplasm

China, United States, Australia, Spain, Korea, Republic of, New Zealand, Germany
University of Rochester

Not yet recruiting

A Telehealth Advance Care Planning Intervention (TeleSICP)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Myeloid Malignancy | Myelodysplastic/Myeloproliferative Neoplasm

United States
Vion Pharmaceuticals

Completed

VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory Leukemia

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder

Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Diseases

United States
European Organisation for Research and Treatment...

Unknown

Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

Belgium, Netherlands, Germany, Italy, United Kingdom, Austria, Czech Republic, Croatia, Turkey, Switzerland
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm

United States
European Working Group of MDS in Childhood

Unknown

Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome

Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

Germany
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Medical Research Council

Completed

Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United Kingdom
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
University of Wisconsin, Madison
National Cancer Institute (NCI)

Completed

Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

Unspecified Childhood Solid Tumor, Protocol Specific | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Neoplasms

United States
Asan Medical Center

Completed

Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

Korea, Republic of
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Recurrent Myeloproliferative Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Southwest Oncology Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Completed

S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
National Cancer Institute (NCI)

Completed

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Neoplasms

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Ehab L Atallah

Completed

Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN)

Myelodysplastic Syndromes

United States
Masonic Cancer Center, University of Minnesota

Recruiting

PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation

Lymphoma | Myelodysplastic Syndromes | Acute Leukemia | Myeloproliferative Neoplasm

United States
University Health Network, Toronto

Completed

Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm (DSC-SR)

Myelodysplastic/Myeloproliferative Neoplasm | Allogeneic Hematopoietic Cell Transplant | Steroid Refractory GVHD

Canada
Stanford University
National Institutes of Health (NIH)

Completed

Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders

Myelodysplastic Syndromes | Myeloproliferative Disorders | Myelodysplastic Syndromes (MDS) | Blood and Marrow Transplant (BMT) | Myeloproliferative Disorders (MPD)

United States
Ohio State University Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.; Celgene Corporation

Completed

Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease

United States

Clinical Trials on Vorübergehendes myeloproliferatives Syndrom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations